At a glance
ClinicalIndex Comparison RecordN/ACompleted· 119 enrolled
Drug / intervention
Chemotherapy +1 moredrug
Likely dose
Chemotherapy 1000mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective Phase Ⅱ Clinical Study of Stereotactic Radiotherapy Combined With Chemotherapy With Different Biological Effective Doses (<70gy vs. >70Gy) in Locally Advanced Pancreatic Cancer
In Brief
A clinical study evaluating SBRT and Chemotherapy for Treatment. Completed, enrolled 119 participants across 2 sites.
Detailed Summary
The aim of this study is to compare the safety and efficacy of SBRT in LAPC with different biological effective dose (BED) (\<70Gy Vs.\>70Gy ) , to identify a dose range that could achieve better survival benefit and minimize the toxicity of radiotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTreatment
CountriesChina
Collaborators--
Timeline
N/ACompletedFinished
202120222023202420252026
First PostedOct 2020
Enrollment StartNov 2020
Primary CompletionAug 2025
TodayJul 2026
First PostedOct 27, 2020
Enrollment StartNov 10, 2020
Primary CompletionAug 15, 2025
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 5.7 years ago
Interventions
SBRTradiation
SBRT: in 5-6 fractions with CyberKnife
Chemotherapydrug
Gemcitabine 1000mg/m\^2 and nab-paclitaxel 125mg/m\^2, administered intravenously, on day 1 and 8 of a 21-day cycle for six cycles